TY - JOUR
T1 - Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis
AU - S:CORT consortium
AU - Leach, Joshua D.G.
AU - Vlahov, Nikola
AU - Tsantoulis, Petros
AU - Ridgway, Rachel A.
AU - Flanagan, Dustin J.
AU - Gilroy, Kathryn
AU - Sphyris, Nathalie
AU - Vázquez, Ester G.
AU - Vincent, David F.
AU - Faller, William J.
AU - Hodder, Michael C.
AU - Raven, Alexander
AU - Fey, Sigrid
AU - Najumudeen, Arafath K.
AU - Strathdee, Douglas
AU - Nixon, Colin
AU - Hughes, Mark
AU - Clark, William
AU - Shaw, Robin
AU - Maughan, Tim
AU - Salto-Tellez, Manuel
AU - Quirke, Philip
AU - Koelzer, Viktor
AU - Dunne, Philip
AU - Beggs, Andrew
AU - Campbell, Peter
AU - Buffa, Francesca
AU - Holmes, Chris
AU - Kaplan, Rick
AU - Brown, Louise
AU - Lawler, Mark
AU - Hordern, Joshua
AU - Tomlinson, Ian
AU - Leedham, Simon
AU - Morton, Dion
AU - van Hooff, Sander R.
AU - Huels, David J.
AU - Medema, Jan Paul
AU - Barry, Simon T.
AU - Frame, Margaret C.
AU - Unciti-Broceta, Asier
AU - Leedham, Simon J.
AU - Inman, Gareth J.
AU - Jackstadt, Rene
AU - Thompson, Barry J.
AU - Campbell, Andrew D.
AU - Tejpar, Sabine
AU - Sansom, Owen J.
N1 - Publisher Copyright:
© 2021, The Author(s).
PY - 2021/12/1
Y1 - 2021/12/1
N2 - Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and TGFβ signalling. Here, we describe a mouse model of right-sided colon cancer driven by oncogenic BRAF and loss of epithelial TGFβ-receptor signalling. The proximal colonic tumours that develop in this model exhibit a foetal-like progenitor phenotype (Ly6a/Sca1+) and, importantly, lack expression of Lgr5 and its associated intestinal stem cell signature. These features are recapitulated in human BRAF-mutant, right-sided CRCs and represent fundamental differences between left- and right-sided disease. Microbial-driven inflammation supports the initiation and progression of these tumours with foetal-like characteristics, consistent with their predilection for the microbe-rich right colon and their antibiotic sensitivity. While MAPK-pathway activating mutations drive this foetal-like signature via ERK-dependent activation of the transcriptional coactivator YAP, the same foetal-like transcriptional programs are also initiated by inflammation in a MAPK-independent manner. Importantly, in both contexts, epithelial TGFβ-receptor signalling is instrumental in suppressing the tumorigenic potential of these foetal-like progenitor cells.
AB - Right-sided (proximal) colorectal cancer (CRC) has a poor prognosis and a distinct mutational profile, characterized by oncogenic BRAF mutations and aberrations in mismatch repair and TGFβ signalling. Here, we describe a mouse model of right-sided colon cancer driven by oncogenic BRAF and loss of epithelial TGFβ-receptor signalling. The proximal colonic tumours that develop in this model exhibit a foetal-like progenitor phenotype (Ly6a/Sca1+) and, importantly, lack expression of Lgr5 and its associated intestinal stem cell signature. These features are recapitulated in human BRAF-mutant, right-sided CRCs and represent fundamental differences between left- and right-sided disease. Microbial-driven inflammation supports the initiation and progression of these tumours with foetal-like characteristics, consistent with their predilection for the microbe-rich right colon and their antibiotic sensitivity. While MAPK-pathway activating mutations drive this foetal-like signature via ERK-dependent activation of the transcriptional coactivator YAP, the same foetal-like transcriptional programs are also initiated by inflammation in a MAPK-independent manner. Importantly, in both contexts, epithelial TGFβ-receptor signalling is instrumental in suppressing the tumorigenic potential of these foetal-like progenitor cells.
UR - http://www.scopus.com/inward/record.url?scp=85107830538&partnerID=8YFLogxK
U2 - 10.1038/s41467-021-23717-5
DO - 10.1038/s41467-021-23717-5
M3 - Article
C2 - 34103493
AN - SCOPUS:85107830538
VL - 12
JO - Nature Communications
JF - Nature Communications
SN - 2041-1723
IS - 1
M1 - 3464
ER -